Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function

PLoS Pathogens

Volumn 12, Issue 8, 2016, Pages

  Pace, Matthew ^a,b   Williams, James ^a   Kurioka, Ayako ^a   Gerry, Andrew B ^c   Jakobsen, Bent ^c   Klenerman, Paul ^a,b,d   Nwokolo, Nneka ^e   Fox, Julie ^f   Fidler, Sarah ^g   Frater, John ^a,b,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Adaptimmune Ltd   (United Kingdom)

^d NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAG PROTEIN; HISTONE DEACETYLASE INHIBITOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NEF PROTEIN; PANOBINOSTAT; ROMIDEPSIN; VORINOSTAT;

ARTICLE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NATURAL KILLER CELL; CELL CULTURE; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; VIROLOGY; VIRUS LATENCY;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; KILLER CELLS, NATURAL; VIRUS LATENCY;

EID: 84984799753     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005782     Document Type: Article

References (33)

1. Pace M, Frater J, A cure for HIV: is it in sight?Expert review of anti-infective therapy. 2014;12(7):783–91. doi: 10.1586/14787210.2014.91011224745361
2. Wightman F, Ellenberg P, Churchill M, Lewin SR, HDAC inhibitors in HIV. Immunology and cell biology. 2012;90(1):47–54. doi: 10.1038/icb.2011.9522083528
3. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487(7408):482–5. Epub 2012/07/28. doi: 10.1038/nature1128622837004
4. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS pathogens. 2014;10(10):e1004473. doi: 10.1371/journal.ppat.100447325393648
5. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. The Lancet HIV. 2014;1(1):e13–e21. doi: 10.1016/S2352-3018(14)70014-126423811
6. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity. 2012;36(3):491–501. Epub 2012/03/13 doi: 10.1016/j.immuni.2012.01.01422406268
7. Jones RB, O'Connor R, Mueller S, Foley M, Szeto GL, Karel D, et al. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS pathogens. 2014;10(8):e1004287. doi: 10.1371/journal.ppat.100428725122219
8. Kaufman DS, Schoon RA, Leibson PJ, Role for major histocompatibility complex class I in regulating natural killer cell-mediated killing of virus-infected cells. Proceedings of the National Academy of Sciences of the United States of America. 1992;89(17):8337–41. 1325654
9. Schaefer MR, Wonderlich ER, Roeth JF, Leonard JA, Collins KL, HIV-1 Nef targets MHC-I and CD4 for degradation via a final common beta-COP-dependent pathway in T cells. PLoS pathogens. 2008;4(8):e1000131. doi: 10.1371/journal.ppat.100013118725938
10. Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. Journal of immunology. 2000;165(12):7017–24.
11. Pellicciotta I, Cortez-Gonzalez X, Sasik R, Reiter Y, Hardiman G, Langlade-Demoyen P, et al. Presentation of telomerase reverse transcriptase, a self-tumor antigen, is down-regulated by histone deacetylase inhibition. Cancer research. 2008;68(19):8085–93. doi: 10.1158/0008-5472.CAN-08-101418829567
12. Falkenberg KJ, Johnstone RW, Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nature reviews Drug discovery. 2014;13(9):673–91. doi: 10.1038/nrd436025131830
13. Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nature medicine. 2008;14(12):1390–5. Epub 2008/11/11. doi: 10.1038/nm.177918997777
14. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A, et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. The Journal of experimental medicine. 2007;204(12):3027–36. 18025129
15. Williams JP, Southern P, Lissina A, Christian HC, Sewell AK, Phillips R, et al. Application of magnetic field hyperthermia and superparamagnetic iron oxide nanoparticles to HIV-1-specific T-cell cytotoxicity. International journal of nanomedicine. 2013;8:2543–54. Epub 2013/08/01. doi: 10.2147/IJN.S4401323901272
16. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF, New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nature medicine. 2014;20(4):425–9. doi: 10.1038/nm.348924658076
17. Cooper MA, Fehniger TA, Caligiuri MA, The biology of human natural killer-cell subsets. Trends in immunology. 2001;22(11):633–40. 11698225
18. Khan AN, Gregorie CJ, Tomasi TB, Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer immunology, immunotherapy: CII. 2008;57(5):647–54. 18046553
19. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L, Targeting natural killer cells and natural killer T cells in cancer. Nature reviews Immunology. 2012;12(4):239–52. doi: 10.1038/nri317422437937
20. Nolting A, Dugast AS, Rihn S, Luteijn R, Carrington MF, Kane K, et al. MHC class I chain-related protein A shedding in chronic HIV-1 infection is associated with profound NK cell dysfunction. Virology. 2010;406(1):12–20. doi: 10.1016/j.virol.2010.05.01420667578
21. Fogli M, Mavilio D, Brunetta E, Varchetta S, Ata K, Roby G, et al. Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals. PLoS pathogens. 2008;4(7):e1000101. doi: 10.1371/journal.ppat.100010118617991
22. Ward J, Bonaparte M, Sacks J, Guterman J, Fogli M, Mavilio D, et al. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood. 2007;110(4):1207–14. 17513617
23. Jost S, Altfeld M, Evasion from NK cell-mediated immune responses by HIV-1. Microbes Infect. 2012;14(11):904–15. doi: 10.1016/j.micinf.2012.05.00122626930
24. Ogbomo H, Michaelis M, Kreuter J, Doerr HW, Cinatl J, JrHistone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS letters. 2007;581(7):1317–22. 17349632
25. Shi P, Yin T, Zhou F, Cui P, Gou S, Wang C, Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway. BMC cancer. 2014;14:370. doi: 10.1186/1471-2407-14-37024885711
26. Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau CC, Gottschalk SM, et al. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharmaceutical research. 2015;32(3):779–92. doi: 10.1007/s11095-013-1231-024203492
27. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS pathogens. 2014;10(4):e1004071. doi: 10.1371/journal.ppat.100407124722454
28. Shapiro GI, Frank R, Dandamudi UB, Hengelage T, Zhao L, Gazi L, et al. The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. Cancer Chemother Pharmacol. 2012;69(2):555–62. doi: 10.1007/s00280-011-1758-x22057852
29. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. The Journal of clinical investigation. 2015;125(5):1901–12. doi: 10.1172/JCI8014225822022
30. Pace MJ, Graf EH, Agosto LM, Mexas AM, Male F, Brady T, et al. Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS pathogens. 2012;8(7):e1002818. Epub 2012/08/23. doi: 10.1371/journal.ppat.100281822911005
31. Zhang ZM, Guan X, Li YJ, Zhu MC, Yang XJ, Zou X, HLA Class I Expressions on Peripheral Blood Mononuclear Cells in Colorectal Cancer Patients. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2012;24(1):77–82. doi: 10.1007/s11670-012-0077-z23359566
32. Suarez-Alvarez B, Rodriguez RM, Calvanese V, Blanco-Gelaz MA, Suhr ST, Ortega F, et al. Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells. PloS one. 2010;5(4):e10192. doi: 10.1371/journal.pone.001019220419139
33. Bokhoven M, Stephen SL, Knight S, Gevers EF, Robinson IC, Takeuchi Y, et al. Insertional gene activation by lentiviral and gammaretroviral vectors. Journal of virology. 2009;83(1):283–94. doi: 10.1128/JVI.01865-0818945765